2004
DOI: 10.1002/chin.200417151
|View full text |Cite
|
Sign up to set email alerts
|

A Facile Synthesis of New 3‐Substituted‐2,3‐dihydropyrido[3,2‐d]pyrimidine‐2,4‐diones.

Abstract: Fused pyrimidine derivativesFused pyrimidine derivatives R 0515 A Facile Synthesis of New 3-Substituted-2,3-dihydropyrido[3,2-d]pyrimidine-2,4-diones. -Two efficient routes for the synthesis of the title compounds (IV) starting from inexpensive 2,3-pyridinedicarboxylic acid monoester (I) are reported. The first method involves the heterocyclization of urea derivatives (V) derived from isocyanate (II), the second and more efficient route uses direct condensation of the isocyanate (II) with different arylalkylam… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2010
2010
2010
2010

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 1 publication
0
1
0
Order By: Relevance
“…Pyridopyrimidine has wide range of biological activity, particularly in cancer and virus research (Berthelot, 1859;Mamouni et al, 2003;David et al, 1997). The pyridopyrimidine is of interest as inhibitor of dihydrofolate reductase (Mihailo et al, 2009) but also for its antibacterial, antifungal (Miller et al, 2009;Sayed et al, 2005), antitumor (Cockerill et al, 2001), adenosine kinase inhibitors (Gfesser et al, 2003;Cowart et al, 2001) activities and recently as excellent potent Akt1/2 Inhibitors (Wu et al, 2008).…”
Section: Introductionmentioning
confidence: 99%
“…Pyridopyrimidine has wide range of biological activity, particularly in cancer and virus research (Berthelot, 1859;Mamouni et al, 2003;David et al, 1997). The pyridopyrimidine is of interest as inhibitor of dihydrofolate reductase (Mihailo et al, 2009) but also for its antibacterial, antifungal (Miller et al, 2009;Sayed et al, 2005), antitumor (Cockerill et al, 2001), adenosine kinase inhibitors (Gfesser et al, 2003;Cowart et al, 2001) activities and recently as excellent potent Akt1/2 Inhibitors (Wu et al, 2008).…”
Section: Introductionmentioning
confidence: 99%